SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC
SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC
Recruiting · NCT06927180 · Registry updated 2025-06-23Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC | Disease Attributes, Disease Progression, Neoplasms by Site, Pathologic Complete Response, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 2 | 2025-06-23 | NCT06927180 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Henan Cancer Hospital | 147 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Henan Cancer Hospital | Zhengzhou | China | 98 |